More on ERAS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (8.5 Score)

Upcoming Events

- Earnings (5/8/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Erasca, Inc (NQ:ERAS)
Delayed: 15.47 -0.07 (0.45%)
Prev. Close $15.54  
Open$15.58 
52 Wk High$ 
52 Wk Low$ 
Day High$15.97 
Day Low$14.97 
P/E N/A  
EPS$ 
Volume5,052,073 

Friends, Peers and Foes (?): RVMD, ONCY, BBOT, ALXO, IMRX (more...)

Mar 6, 2026 09:00 AM Form 4 Erasca, Inc. For: Mar 04 Filed by: Morris Shannon
Mar 5, 2026 05:16 PM Erasca Inc (ERAS) PT Raised to $20 at Clear Street
Mar 5, 2026 07:01 AM Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
Mar 4, 2026 05:39 PM Form 144 Erasca, Inc. Filed by: Morris Shannon
Feb 24, 2026 08:00 AM Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
Feb 17, 2026 02:27 PM Form 144 Erasca, Inc. Filed by: Erasca Foundation
Feb 17, 2026 10:48 AM Registration Momentum Builds Across the Oncology Pipeline
Feb 17, 2026 10:29 AM Form SCHEDULE 13G/A Erasca, Inc. Filed by: T. Rowe Price Investment Management, Inc.
Feb 9, 2026 07:29 AM Erasca (ERAS) Reiterated at Buy by Stifel: Chinese 'me too Assets' Unlikely
Feb 5, 2026 08:00 AM Erasca to Present at Upcoming Conferences in February
View All Articles

Entities mentioned with ERAS

View All Entities